Faculty profile

Pierre-Olivier Fiset

ResearcherMcGill University

This profile is built from public research funding records (CIHR, NSERC and SSHRC) and PubMed. We have not imported them from a McGill University directory, so their courses and email address may be missing. Find their university profile.

Pierre-Olivier Fiset

Researcher

Health Sciences

McGill University

Montreal, Quebec, Canada

Supervision signals

Has led research grants, which requires an independent research appointment. Ask their department whether they supervise graduate students.
14 publications in the last five years, latest in 2026.
Principal investigator on 1 research grant (1 CIHR), most recently in 2021.

These signals come from public records, including CIHR, NSERC and SSHRC funding decisions. Ask the professor or the graduate program whether they are taking new students.

Academic metrics

Publications

Citations

h-index

Collaborators

Grants

Publications by year

Counts cover the works listed on the university profile; citation counts come from Dimensions.

Profiles and links

Search on Google Scholar

Find them onX · LinkedIn · Bluesky · YouTube

Signals and details

Research

Biomarkers Targets

Latest papers

Perioperative Avelumab and Chemotherapy for Gastroesophageal Adenocarcinoma: Long-Term Survival Outcomes.
International journal of cancer · 2026
Neoadjuvant Chemotherapy-Immunotherapy in Non-Small Cell Lung Cancer: Can Positron Emission Tomography Scan Predict Complete Pathologic Response?
The Annals of thoracic surgery · 2026
TP53 co-mutations increase risk of recurrence in EGFR-mutated stage I lung adenocarcinoma.
European journal of cancer (Oxford, England : 1990) · 2025

All 26 publications

Latest funding

Unlocking new options for patients with squamous cell carcinoma of the lung
CIHR · 2021 · Nominated PI
$60,000

All 1 grants and awards

26 publications.

Perioperative Avelumab and Chemotherapy for Gastroesophageal Adenocarcinoma: Long-Term Survival Outcomes.

Alcindor T, Tankel J, Fiset PO, Dehghani M, Bertos N, Mueller C, Cools-Lartigue J, Camilleri-Broet S, Ferri L

International journal of cancer2026

DOI: 10.1002/ijc.70749 PMID: 42750489

Neoadjuvant Chemotherapy-Immunotherapy in Non-Small Cell Lung Cancer: Can Positron Emission Tomography Scan Predict Complete Pathologic Response?

Seitlinger J, Salko O, Bulgarelli Maqueda L, Meng A, Têtu M, Desilets A, Owen S, Shieh B, Wong A, Ofiara L, Agulnik J, Fiset PO, Malo J, Blais N, Florescu M, Tehfe M, Ferraro P, Nasir B, Cools-Lartigue J, Najmeh S, Juneau D, Elkrief A, Ferri L, Routy B, Liberman M, Spicer JD

The Annals of thoracic surgery2026

DOI: 10.1016/j.athoracsur.2025.09.051 PMID: 41167577

TP53 co-mutations increase risk of recurrence in EGFR-mutated stage I lung adenocarcinoma.

Gallina FT, Marinelli D, Tajè R, Visca P, Cecere FL, Landi L, Buglioni S, Forcella D, Melis E, Najmeh S, Rayes R, Cools-Lartigue J, Camilleri-Broët S, Fiset PO, Ferri L, Cappuzzo F, Spicer J

European journal of cancer (Oxford, England : 1990)2025

DOI: 10.1016/j.ejca.2025.115622 PMID: 40680467

KRAS ctDNA Detection in Patients With Resectable Lung Adenocarcinoma.

De Meo ML, Seitlinger J, Rayes RF, Walsh LC, Shahzad MH, Tsering T, Saleh R, Ezer N, Shieh B, Wong A, Owen S, Walsh L, Fiset PO, Burnier JV, Spicer JD

Clinical lung cancer2025

DOI: 10.1016/j.cllc.2025.05.006 PMID: 40634198

A fibroblast-centric network drives cold fibrosis in the tumor microenvironment of lung squamous cell carcinoma.

Miyara S, Frenkel S, Mayo A, Gascard P, Strasser M, Gibbs D, Weizman E, Shalom IB, Stein Y, Pan D, Caruso JA, Sangwan V, Bertos N, Berube J, Camilleri-Broet S, Oikonomopoulos S, Djambazian H, Umansky KB, Elkahal J, Mayer S, Fiset PO, Ragoussis J, Adler M, Tzahor E, Huang S, Ferri L, Tlsty TD, Scherz-Shouval R, Alon U

bioRxiv : the preprint server for biology2025

DOI: 10.1101/2025.08.25.668405 PMID: 40909739

Phase 2 trial of perioperative chemo-immunotherapy for gastro-esophageal adenocarcinoma: The role of M2 macrophage landscape in predicting response.

Alcindor T, Tankel J, Fiset PO, Pal S, Opu T, Strasser M, Dehghani M, Bertos N, Zuo D, Mueller C, Cools-Lartigue J, Hickeson M, Marcus V, Camilleri-Broet S, Spatz A, Evaristo G, Farag M, Artho G, Elkrief A, Saleh R, Bailey S, Park M, Huang S, Sangwan V, Ferri L

Cell reports. Medicine2025

DOI: 10.1016/j.xcrm.2025.102045 PMID: 40239627

Spatially mapping the tumour immune microenvironments of non-small cell lung cancer.

Desharnais L, Sorin M, Rezanejad M, Liu B, Karimi E, Atallah A, Swaby AM, Yu MW, Doré S, Hartner S, Fiset B, Wei Y, Kadang B, Rayes R, Joubert P, Camilleri-Broët S, Fiset PO, Quail DF, Spicer JD, Walsh LA

Nature communications2025

DOI: 10.1038/s41467-025-56546-x PMID: 39905080

Exomic and epigenomic analysis of pulmonary blastoma.

Alirezaie N, Chong AL, Kommoss FKF, Sabbaghian N, Camacho Valenzuela J, Pelletier D, Nadaf J, Kolekar SB, Sivapalan P, Evans MG, Thorner PS, Fiset PO, von Deimling A, Foulkes WD

Lung cancer (Amsterdam, Netherlands)2024

DOI: 10.1016/j.lungcan.2024.107916 PMID: 39121796

Transitioning to Neoadjuvant Therapy for Resectable Non-Small Cell Lung Cancer: Trends and Surgical Outcomes in a Regionalized Pulmonary Oncology Network.

Pilon Y, Rokah M, Seitlinger J, Sepesi B, Rayes RF, Cools-Lartigue J, Najmeh S, Sirois C, Mulder D, Ferri L, Abdulkarim B, Ezer N, Fraser R, Camilleri-Broët S, Fiset PO, Wong A, Sud S, Langleben A, Agulnik J, Pepe C, Shieh B, Hirsh V, Ofiara L, Owen S, Spicer JD

Clinical lung cancer2024

DOI: 10.1016/j.cllc.2023.12.005 PMID: 38378398

Toward a Total Dataization of Anatomic Pathology: Are You Ready?

Fiset PO, Bigras G

Applied immunohistochemistry & molecular morphology : AIMM2023First author

DOI: 10.1097/pai.0000000000001145 PMID: 37493457

Something wrong or missing on this profile? Suggest a correction

Pierre-Olivier Fiset

Research

Latest papers

Latest funding

Perioperative Avelumab and Chemotherapy for Gastroesophageal Adenocarcinoma: Long-Term Survival Outcomes.

Neoadjuvant Chemotherapy-Immunotherapy in Non-Small Cell Lung Cancer: Can Positron Emission Tomography Scan Predict Complete Pathologic Response?

TP53 co-mutations increase risk of recurrence in EGFR-mutated stage I lung adenocarcinoma.

KRAS ctDNA Detection in Patients With Resectable Lung Adenocarcinoma.

A fibroblast-centric network drives cold fibrosis in the tumor microenvironment of lung squamous cell carcinoma.

Phase 2 trial of perioperative chemo-immunotherapy for gastro-esophageal adenocarcinoma: The role of M2 macrophage landscape in predicting response.

Spatially mapping the tumour immune microenvironments of non-small cell lung cancer.

Exomic and epigenomic analysis of pulmonary blastoma.

Transitioning to Neoadjuvant Therapy for Resectable Non-Small Cell Lung Cancer: Trends and Surgical Outcomes in a Regionalized Pulmonary Oncology Network.

Toward a Total Dataization of Anatomic Pathology: Are You Ready?

Unlocking new options for patients with squamous cell carcinoma of the lung

Frequent collaborators

Lorenzo Ferri

Jonathan Spicer

Arielle Elkrief

Ramy Saleh

Nada Jabado

Nicole Ezer

Peter Metrakos

Steven Gallinger

Morag Park

Talat Bessissow

Mark Sorin

Philippe Joubert

Jean-Pierre Routy

Andrea Benedetti

ATILLA Omeroglu

Morag Park

Jacek Majewski

Guillaume Bourque

Andrew Seely

Logan Walsh

Bertrand Routy

Swneke Bailey

Jean-Pierre Routy